Collectively, in the presence of gut microbiota, SGD can treat CCl4-induced liver injury by inhibiting the over-expression of CYP2E1 to reduce oxidative stress, enhancing antioxidant enzymes to eliminate free radicals, and reducing inflammation. The gene discussed is CYP2E1; the disease is specific granule deficiency.